Physician profile
Indu Sharma
NPI 1982692265
$2,287.04
in general payments reported to CMS, 2019-2025
16 companies · $519 in 2025
The $519 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $313 · 2020: $264 · 2021: $259 · 2022: $461 · 2023: $241 · 2024: $230 · 2025: $519.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $966 · Education: $24.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $966.31 |
| Education | $24.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $699.36 | 2019-2025 | Padcev, Xtandi, Xospata |
| Janssen Biotech, INC. | $628.61 | 2019-2025 | Darzalex, Erleada, Rybrevant |
| Celgene Corporation | $271.99 | 2019-2025 | Reblozyl, Opdualag, Onureg |
| E.R. Squibb & Sons, L.L.C. | $180.48 | 2020-2025 | Opdivo |
| Incyte Corporation | $128.20 | 2019-2025 | Jakafi |
| Octapharma USA, INC. | $102.73 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $76.31 | 2019-2023 | |
| Stemline Therapeutics INC. | $49.96 | 2025 | Orserdu |
| Emd Serono, INC. | $31.69 | 2022-2025 | |
| Akebia Therapeutics INC | $24.61 | 2024 | Vafseo |
| Lilly USA, LLC | $20.44 | 2019 | |
| Eisai INC. | $17.79 | 2025 | |
| Amgen INC. | $14.58 | 2019 | |
| Horizon Therapeutics Plc | $14.38 | 2022 | |
| Foundation Medicine, INC. | $13.64 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beigene USA, INC. | $12.27 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Indu Sharma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.